“Our goal is clear: to transform the cancer experience from fragmented and burdensome to equitable, connected, and ...

Furthermore, GLP-1 drugs had a favorable safety profile versus aspirin, particularly with respect to bleeding events, said ...

Known as Dry January, some are saying "no" to alcohol for the entire month.  Some are even making the decision to abstain ...

From hair regrowth to safe pregnancy chemotherapy and new targeted therapies, these top five breast cancer stories of 2025 ...

Lori Willis, executive director of the Cancer Foundation of Santa Barbara, explained that the class provides participants ...

A new drug application (NDA) has been submitted to the FDA seeking approval of rusfertide, an investigational hepcidin ...

Patients who are prescribed antibiotics during immune checkpoint blockade therapy for solid tumors face a heightened risk for ...

SAN FRANCISCO -- Including encorafenib (Braftovi) and cetuximab (Erbitux) in the first-line treatment of BRAF V600E-mutated ...

Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment ...

Incyte Corporation rated Buy on surging Hem/Onc growth, Monjuvi/Minjuvi catalysts, frontMIND data and strong cash. Click for ...

Studies published in Nature Cancer reveal how bacterial presence in head and neck cancers affects treatment response, ...

The FDA has granted breakthrough therapy designation (BTD) to sevabertinib (Hyrnuo, formerly BAY 2927088) for the first-line ...